Contineum Therapeutics, Inc. (NASDAQ:CTNM – Free Report) – Analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for Contineum Therapeutics in a research report issued to clients and investors on Thursday, September 25th. The consensus estimate for Contineum Therapeutics’ current full-year earnings is ($2.01) per share. Leerink Partnrs also issued estimates for Contineum Therapeutics’ Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.63) EPS, Q1 2026 earnings at ($0.76) EPS, Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.85) EPS and FY2026 earnings at ($2.83) EPS. Get Contineum Therapeutics alerts:A number of other analysts have also recently weighed in on CTNM. Recommended StoriesReceive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.